Navigation Links
Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
Date:9/6/2011

sed drugs."

About Regeneron Pharmaceuticals Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on www.regeneron.com.Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
2. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
3. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
4. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
5. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
6. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
7. Genprex Announces New Branding
8. BioMed Realty Announces Repurchase at Option of Holders and Redemption of 4.50% Exchangeable Senior Notes Due 2026
9. BioInformatics LLC Announces the Life Science Industry Awards on November 15, 2011 in Washington, DC
10. Jeunesse Global Announces New Medical Advisory Board Member and Admittance Into the Direct Selling Association (DSA).
11. BD Biosciences Announces Winners of Research Grant Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... --  Epic Sciences, Inc. ("Epic"), a private biotech ... and advance the treatment and management of cancer, announced ... as chairman of Epic,s board of directors. Mr. Lucier ... Invitrogen). Mr. Lucier joins Epic,s board of directors to ... analysis platform with special focus on the development of ...
(Date:7/30/2014)... , July 30, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... RXI-109, for the reduction of recurrence of ... has been initiated. Logo - ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Connecticut Center ... organization based in East Hartford, Conn., was awarded a ... II of a project that will determine the feasibility ... rural north-central Connecticut. USDA Rural Development provided $53,000 for ... for the second phase of the feasibility study in ...
(Date:7/30/2014)... Adding to their already extensive selection ... – Buy 2 of any Weighing Boats or ... lab technicians looking for durable and reliable weighing products ... multiple applications including weighing liquids, solid, or granulated samples. ... diamond-shaped, hexagonal, square, aluminum weighing, and standard boats. Aluminum ...
Breaking Biology Technology:Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3Weighing Boat Promotion Now Available at Pipette.com, Major Pipette Distributor 2
... NORTH VANCOUVER, April 16 /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ... on its on-going restructuring efforts., The Board of ... stepped down as President and Chief Executive Officer, effective,immediately. ... Mr. Duncan, a,founder of the Company, served as President ...
... Annual Meeting of the American ... Association for Cancer Research (AACR) -, ... LOR; AMEX: LRP), a biopharmaceutical company specializing,in the research, ... management of cancer, today announced,presentations of further preclinical data ...
... the National Institute of Standards and Technology (NIST) ... on a single microchip, a cryogenic sensor and ... cheaper, simpler and faster precision analysis of materials ... in an upcoming issue of Applied Physics Letters,* ...
Cached Biology Technology:Chromos provides shareholder update 2Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 2Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 3Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 4NIST micro sensor and micro fridge make cool pair 2
(Date:7/30/2014)... cells types. Researchers would like to understand how to channel ... make up the organs and other structures of living organisms. ... sugars that dangle from proteins on surfaces of cells. , ... has created synthetic molecules that can stand in for the ... the process, they report in the Journal of the ...
(Date:7/30/2014)... the first high-resolution map of the carbon stocks ... Per. The new and improved methodology used to ... future market-based carbon economies. The new carbon ... and it provides the critical input to studies ... use, and enforcement purposes. The technique includes the ...
(Date:7/29/2014)... USA The advanced optical methods and applications for ... a revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics. , ... BRAIN Initiative in the United States, and a special ... and provide examples of the impact that optics and ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3
... Memorial Sloan-Kettering Cancer Center have discovered that a new class ... work best in patients with mutations in the BRAF gene. ... the growth and survival of cancer cells and is mutated ... minority of patients with colon, breast, and lung cancers. The ...
... For the first time, ultrasound is being used in animal ... at the University of Pennsylvania School of Medicine completed a ... see a tumor's blood perfusion and then to treat it ... of treatment at an intensity similar to what is used ...
... week in Current Biology, tsunami damage to coral reefs ... was occasionally spectacular, but surprisingly limited, particularly when compared ... , Less than 100 days after the tsunami ... James Cook University, the Wildlife Conservation Society-Indonesia Program, and ...
Cached Biology News:Mutations in the BRAF gene predict sensitivity to a novel class of cancer drugs 2Penn researchers study the use of ultrasound for treatment of cancer 2
Rabbit polyclonal to Quinaldic Acid ( Abpromise for all tested applications). Antigen: Synthetic peptide Quinaldic Acid conjugated to a protein carrier....
Recommended for supporting the growth of anchorage-dependent cells including human and mouse stromal cells, mesenchymal cells and cell lines....
ID clarifier: With ethidium bromide (50 μg/ml)...
... Propidium Iodide (PI) is a fluorescent nucleic ... nucleic acids. As a nuclear counterstain, ... dark red in color. The fluorescent ... or blue fluorochromes such as FITC, Cy2 ...
Biology Products: